Novo Nordisk Education Foundation launches Chatbot, Mishti for diabetes management in India

Published On 2021-07-20 05:45 GMT   |   Update On 2021-07-20 11:53 GMT
Advertisement

New Delhi: Novo Nordisk Education Foundation on Monday said it has launched Chatbot, Mishti aiming to provide access to important information to effectively manage diabetes in India.

It is customised in seven different languages -- English, Hindi, Bengali, Gujarati, Marathi, Punjabi, and Tamil, so that a greater number of people can access the information in their preferred language, Novo Nordisk Education Foundation (NNEF) said in a statement.

Advertisement

Some of the key information services offered by Mishti include insulin device demos, customised diet plans for each patient with exercise guidance based on publicly available information, and scientifically backed research papers, it added.

Read also: Unichem Labs diabetes drug Sitagliptin gets USFDA approval

"The pandemic has made us realise the importance of effectively managing diabetes to prevent various complications and co-morbidities. With digital transformation being the need of the hour, we must constantly innovate to provide digital solutions with a patient-centric approach," NNEF Managing Trustee Vikrant Shrotriya said.

Mishti delivers diabetes-centric information to people through Whatsapp, NNEF said.

Read also: Semaglutide to be sold only on prescription of Endocrinologist, PG Medicine in India: CDSCO Committee



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News